Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases

Next Previous
Trial Profile

An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisantaspase (Primary) ; Crisantaspase (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Jazz Pharmaceuticals Inc

Most Recent Events

  • 12 Dec 2023 Results (final cutoff date of November 22, 2022) presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 30 Nov 2023 According to a Jazz Pharmaceuticals plc media release, data from this trial will be presented at the at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12.
  • 22 Sep 2023 According to a Ligand Pharmaceuticals media release, The European Commission approval extends to all European Union Member states, as well as Iceland, Norway, and Liechtenstein.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top